Castle Biosciences Inc.

Castle Biosciences is a molecular diagnostics company that provides innovative test solutions to assist clinicians in diagnosing and treating dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma (UM). Since its inception in 2008, the company has focused on transforming disease management. Its testing solutions are designed to provide personalized information to inform clinical care decisions. For core tissue-based tests, Castle Biosciences uses multi-analyte assays with algorithmic analysis (MAAA) to characterize a patient's biology and generate clinically actionable information, which can guide treatment and patient management decisions, including potential responsiveness to therapy and disease diagnosis. The company's portfolio includes tests for cancers or precancerous diagnoses in dermatology, gastroenterology, and ophthalmology, and a test to guide systemic treatment decisions for patients with moderate-to-severe AD. The clinical validity and utility of its test portfolio are supported by approximately 158 peer-reviewed articles. Commercially available tests include DecisionDx-Melanoma, DecisionDx-SCC, and MyPath Melanoma in Dermatology; TissueCypher in Gastroenterology; and DecisionDx-UM in Ophthalmology. The AdvanceAD-Tx test commenced a limited launch in November 2025.